

02-13-02

A
Box seq

Practitioner's Docket No. MWH-0007US

PATENT

Preliminary Classification:

Proposed Class: 435; 536

Subclass: 5, 69.1, 320.1, 440; 23.1, 24.1

Prior Application:

Art Unit: 1631

Examiner: Mary K. Zeman

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application
 Assistant Commissioner for Patents
 Washington, D.C. 20231

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor(s): Anne Chew; R. Rex Denton; Amy Duda; Stefanie E. Kliem; Elizabeth M. Brown;
 Krishnan Nandabalan; J. Claiborne Stephens

For (title): Haplotypes of the FCER1A Gene

1. Type of Application

This transmittal is for a continuation-in-part (C-I-P) application.

CERTIFICATION UNDER 37 C.F.R. § § 1.8(a) and 1.10*
(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner of Patents, Washington D.C. 20231☐ with sufficient postage as first class mail.

☒ as "Express Mail Post Office to Addressee" Mailing Label
 No. EL59465695345

TRANSMISSION

☐ facsimile transmitted to the Patent and Trademark Office, 703 _____

Date: 2.11.02

Signature

CATHY A. WILCOX

Type or print name of person certifying

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

2. Benefit of Prior U.S. Application (35 U.S.C. Sections 119(e), 120, or 121)

The new application being transmitted claims the benefit of pending International Application PCT/US00/21097 filed August 2, 2000, which claims priority to U.S. Provisional Application 60/147,860 filed August 9, 1999.

3. Papers Enclosed

A. Required for filing date under 37 C.F.R. 1.53(b) (Regular) or 37 C.F.R. 1.153 (Design) Application

45 Page(s) of Specification

22 Page(s) of Claims

6 Sheet(s) of Drawing(s)--Formal

B. Other Papers Enclosed

8 Page(s) of declaration and power of attorney

1 Page(s) of abstract

27 Page(s) of Sequence Listing

4. Additional Papers Enclosed

Information Disclosure Statement (37 C.F.R. 1.98)

Form PTO-1449 (PTO/SB/08A and 08B)

Eleven cited references

Submission of "Sequence Listing," computer readable copy and accompanying statement.

5. Declaration or Oath

Enclosed

Executed by:

All the inventors.

6. Inventorship Statement

The inventorship for all the claims in this application is the same.

7. Language

English

8. Fee Calculation (37 C.F.R. Section 1.16)

Regular Application

CLAIMS AS FILED

Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 CFR 1.16(a) \$740.00
Total Claims (37 CFR 1.16(c))	32	- 20 =	12 x	\$18.00	\$216.00
Independent Claims (37 CFR 1.16(b))	16	- 3 =	13 x	\$84.00	\$1,092.00
Multiple Dependent Claim(s), if any (37 CFR 1.16(d))			+	\$280.00	\$0.00

Filing Fee Calculation

\$2,048.00

9. Fee Payment Being Made at This Time

Enclosed

Filing Fee

\$2,048.00

Total Fees Enclosed

\$2,048.00

10. Method of Payment of Fees

Charge Account No. 50-1293 in the amount of \$2,048.00.

A duplicate of this transmittal is attached.

11. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 50-1293.

37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)

37 C.F.R. Section 1.17 (application processing fees)


12. Instructions as to Overpayment

Credit Account No. 50-1293.

Date: Feb. 11, 2002

Reg. No. 47,562
Tel. No. 203-786-3473

Customer No. 25106


Gisela M. Field
Genaissance Pharmaceuticals, Inc.
5 Science Park
New Haven, CT 06511

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chew, Anne; Denton, R. Rex; Duda, Amy; Kliem, Stefanie E.; Brown, Elizabeth M.; Nandabalan, Krishnan; and Stephens, J. Claiborne

Application No.: To Be Assigned
Filed: February 11, 2002

Group No.: 1631
Examiner: Mary K. Zeman

For: Haplotypes of the FCER1A Gene

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231


STATEMENT ACCOMPANYING SEQUENCE LISTING
(CFR 1.821(f))

The undersigned hereby states upon information and belief that the information recorded in the computer readable form of the Sequence Listing and written Sequence Listing submitted herewith are identical.

Date: 2/11/02

Reg. No.: 47,562
Tel. No.: 203-786-3473

Respectfully submitted,


Gisela M. Field
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511
USA